Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs

Andrew J. Saxon, Dennis McCarty

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The adoption of pharmacotherapies for the treatment of alcohol and drug use disorders has progressed slowly despite the approval of new and effective medications. This paper begins with overviews of the prevalence of alcohol and drug abuse and dependence, the costs of addiction to the nation, and the value of treatment services. The role of pharmacotherapy in the treatment of addictive diseases is examined, and factors that affect the adoption and use of medications for alcohol and drug treatment are identified and discussed. Investigations that tested the effectiveness of buprenorphine for treatment of opioid dependence in new settings illustrate physician and counselor training and mentorship strategies that may promote the adoption of medications in the treatment of alcohol and drug use disorders. The paper concludes with a discussion of barriers and ways to surmount the barriers and to foster greater use of medications in alcohol and drug treatment.

Original languageEnglish (US)
Pages (from-to)119-128
Number of pages10
JournalPharmacology and Therapeutics
Volume108
Issue number1 SPEC. ISS.
DOIs
StatePublished - Oct 2005

Fingerprint

Alcoholism
Substance-Related Disorders
Alcohols
Pharmaceutical Preparations
Therapeutics
Drug Therapy
Buprenorphine
Mentors
Opioid Analgesics
Physicians
Costs and Cost Analysis

Keywords

  • Adoption of innovations
  • Buprenorphine
  • Pharmacotherapy

ASJC Scopus subject areas

  • Pharmacology

Cite this

Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs. / Saxon, Andrew J.; McCarty, Dennis.

In: Pharmacology and Therapeutics, Vol. 108, No. 1 SPEC. ISS., 10.2005, p. 119-128.

Research output: Contribution to journalArticle

@article{6d24623ab1d0472e95c962e517dba378,
title = "Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs",
abstract = "The adoption of pharmacotherapies for the treatment of alcohol and drug use disorders has progressed slowly despite the approval of new and effective medications. This paper begins with overviews of the prevalence of alcohol and drug abuse and dependence, the costs of addiction to the nation, and the value of treatment services. The role of pharmacotherapy in the treatment of addictive diseases is examined, and factors that affect the adoption and use of medications for alcohol and drug treatment are identified and discussed. Investigations that tested the effectiveness of buprenorphine for treatment of opioid dependence in new settings illustrate physician and counselor training and mentorship strategies that may promote the adoption of medications in the treatment of alcohol and drug use disorders. The paper concludes with a discussion of barriers and ways to surmount the barriers and to foster greater use of medications in alcohol and drug treatment.",
keywords = "Adoption of innovations, Buprenorphine, Pharmacotherapy",
author = "Saxon, {Andrew J.} and Dennis McCarty",
year = "2005",
month = "10",
doi = "10.1016/j.pharmthera.2005.06.014",
language = "English (US)",
volume = "108",
pages = "119--128",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "1 SPEC. ISS.",

}

TY - JOUR

T1 - Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs

AU - Saxon, Andrew J.

AU - McCarty, Dennis

PY - 2005/10

Y1 - 2005/10

N2 - The adoption of pharmacotherapies for the treatment of alcohol and drug use disorders has progressed slowly despite the approval of new and effective medications. This paper begins with overviews of the prevalence of alcohol and drug abuse and dependence, the costs of addiction to the nation, and the value of treatment services. The role of pharmacotherapy in the treatment of addictive diseases is examined, and factors that affect the adoption and use of medications for alcohol and drug treatment are identified and discussed. Investigations that tested the effectiveness of buprenorphine for treatment of opioid dependence in new settings illustrate physician and counselor training and mentorship strategies that may promote the adoption of medications in the treatment of alcohol and drug use disorders. The paper concludes with a discussion of barriers and ways to surmount the barriers and to foster greater use of medications in alcohol and drug treatment.

AB - The adoption of pharmacotherapies for the treatment of alcohol and drug use disorders has progressed slowly despite the approval of new and effective medications. This paper begins with overviews of the prevalence of alcohol and drug abuse and dependence, the costs of addiction to the nation, and the value of treatment services. The role of pharmacotherapy in the treatment of addictive diseases is examined, and factors that affect the adoption and use of medications for alcohol and drug treatment are identified and discussed. Investigations that tested the effectiveness of buprenorphine for treatment of opioid dependence in new settings illustrate physician and counselor training and mentorship strategies that may promote the adoption of medications in the treatment of alcohol and drug use disorders. The paper concludes with a discussion of barriers and ways to surmount the barriers and to foster greater use of medications in alcohol and drug treatment.

KW - Adoption of innovations

KW - Buprenorphine

KW - Pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=25444517718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444517718&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2005.06.014

DO - 10.1016/j.pharmthera.2005.06.014

M3 - Article

C2 - 16055196

AN - SCOPUS:25444517718

VL - 108

SP - 119

EP - 128

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 1 SPEC. ISS.

ER -